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Melioidosis is a severe and fatal infectious disease in the tropics and subtropics. It pre-
sents as a febrile illness with protean manifestation ranging from chronic localized
infection to acute fulminant septicemia with dissemination of infection to multiple organs
characterized by abscesses. Pneumonia is the most common clinical presentation.
Because of the wide range of clinical presentations, physicians may often misdiagnose
and mistreat the disease for tuberculosis, pneumonia or other pyogenic infections. The
purpose of this paper is to present common pitfalls in diagnosis and provide optimal
approaches to enable early diagnosis and prompt treatment of melioidosis. Melioidosis
may occur beyond the boundaries of endemic areas. There is no pathognomonic feature
speciﬁc to a diagnosis of melioidosis. In endemic areas, physicians need to expand the
diagnostic work-up to include melioidosis when confronted with clinical scenarios of
pyrexia of unknown origin, progressive pneumonia or sepsis. Radiological imaging is an
integral part of the diagnostic workup. Knowledge of the modes of transmission and risk
factors will add support in clinically suspected cases to initiate therapy. In situations of
clinically highly probable or possible cases where laboratory bacteriological conﬁrmation
is not possible, applying evidence-based criteria and empirical treatment with antimi-
crobials is recommended. It is of prime importance that patients undergo the full course of
antimicrobial therapy to avoid relapse and recurrence. Early diagnosis and appropriate
management is crucial in reducing serious complications leading to high mortality, and in
preventing recurrences of the disease. Thus, there is a crucial need for promoting
awareness among physicians at all levels and for improved diagnostic microbiology
services. Further, the need for making the disease notiﬁable and/or initiating melioidosis
registries in endemic countries appears to be compelling.1. Introduction
Melioidosis is an infectious disease of humans and animals
caused by a gram-negative bacillus, Burkholderia pseudomallei
(B. pseudomallei) that live in moist soil and water. Although the
distribution of melioidosis is concentrated in the tropics and
subtropics, with increasing movement of people between
countries, it may occur in any part of the world. Thus, it may be
considered as a global health problem. Melioidosis has a wide
range of clinical presentations and can be commonlymisdiagnosed and mistreated for other diseases such as tuber-
culosis, common forms of pneumonia or other pyogenic in-
fections. Hence, the disease is often called, ‘the Great Mimicker’
[1]. Despite advances in treatment, the case fatality rates in acute
severe melioidosis is about 30%–47% and may range from 40%
to 75% in cases with sepsis [2]; sepsis appears to be a major
determinant of case fatality. A 20-year prospective study in
Australia reports a 50% case fatality rate among cases with
septic shock and only 4% in the absence of septic shock [3].
About 21%–48% of cases present with septic shock [3–5].
Thus, misdiagnosis of the disease has serious consequences.
Although 20% of community-acquired pneumonia and 20% of
community-acquired sepsis in endemic areas may be due to
B. pseudomallei [1], the disease is not well known among
physicians and microbiologists. Further, based on the ease ofr the CC BY-NC-ND license (http://
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Control and Prevention have classiﬁed B. pseudomallei as a
bioterrorism agent in Category B, the second highest priority
group [6]. Thus, it is crucial for all health care providers to be
aware of the disease. In this paper, we present the common
pitfalls in diagnosis and provide optimal approaches to early
diagnosis and prompt management.
2. Problems in diagnosis and optimal approaches
2.1. Under-diagnosis and under-reporting
Melioidosis occurs primarily in countries with tropical and
sub-tropical climates lying between latitudes 20 ºN and 20 ºS. It
is considered to be endemic in southeast Asia (Brunei,
Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines,
Singapore, Thailand, Timor-Leste and Vietnam), northern
Australia, most of the Indian subcontinent (India, Pakistan,
Bangladesh, Nepal, Bhutan, Sri Lanka, Maldives), southern
China, Hong Kong and Taiwan [7]. Although melioidosis is
endemic in several countries, most published case reports of
melioidosis are only from Thailand, Malaysia, Singapore and
northern Australia (Table 1). Other endemic countries such as
the Indian subcontinent report cases infrequently although the
case volume is expected to be high [4,5,8]. Sporadic cases have
been reported from parts of Africa, the Caribbean, Central and
South America and Middle East. Hence, the known
distribution of the disease is referred to as the ‘tip of the
iceberg’ [9].
The low frequency of reporting in endemic countries reﬂects
under-diagnosis and under-reporting [10]. Missed diagnosis by
physicians coupled with lack of adequate diagnostic
laboratories in rural settings where most of the cases are
expected may contribute to these problems. The disease is not
notiﬁable in most endemic countries [11].
Approach: Under-diagnosis. There is a crucial need to pro-
mote greater awareness and provide improved diagnostic facil-
ities to enable early diagnosis and treatment. Starting withTable 1
Frequency of published case reports.
Southeast Asia and
Northern Australia
(endemic countries)
Other countries
High volume of
cases reported
Cases rarely reported
but case volume
estimated to be high
Sporadic case reports
Malaysia Bangladesh Africa (Gambia, Kenya,
Nigeria and Uganda,
Madagascar)
Northern Australia Brunei Caribbean
Singapore Cambodia Central and
South America
Thailand Hong Kong Mexico
India Middle East
Indonesia
Laos
Myanmar (Burma)
Papua New Guinea
Philippines
Southern China
Sri Lanka
Vietnammedical students, a differential diagnosis of melioidosis should
be entertained, investigated and discussed in all pertinent clinical
scenarios. Continuing medical education on melioidosis is a
useful exercise in all hospitals to increase awareness among
doctors. The topic should be given importance at local and
regional conferences. Protocols for diagnosis and management
need to be in place for urban and for rural hospital/clinic settings
where diagnostic facilities may be unavailable.
Under-reporting. Data are needed to assess the magnitude of
the problem and disease trends across countries. Mandatory
reporting allows for the collection of incidence and mortality
statistics, assessing disease trends and in tracking disease out-
breaks. Jeyaram (2005) states that there is a compelling need to
make the disease notiﬁable in endemic countries [11]. The
disease was made notiﬁable in Singapore in 1989; the data
have been useful in monitoring the disease which indicate a
decreasing trend of incidence and of case fatality [12].
Initiating a melioidosis registry will be another powerful tool
to track the disease, assess treatment and outcomes and to
follow-up patients. For example, Pahang state in Malaysia
began a melioidosis case registry in 2005 which has allowed
them to compile annual statistics and improve management [13];
further, it has helped to increase knowledge among physicians.2.2. Highly variable incubation period
Although melioidosis is endemic in southeast Asia and
northern Australia between latitudes 20 N and 20 S, large
outbreaks have occurred outside this region as in southwestern
Australia [14]. Cases reported from temperate climates are likely
to be due to importing of the disease from the tropics by
immigrants and travelers.
The incubation period (time from exposure to the bacteria to
the onset of symptoms) for the disease may range from one to
21 d (mean, 9 d), but is highly variable [15]. Factors that
inﬂuence the incubation period include the virulence of the
strain, inoculating dose, mode of acquisition and comorbid
conditions in the host. With a high inoculum, as may occur in
cases of aspiration following near-drowning or severe weather
events, the disease may manifest within 24 h [16]. The longest
recorded incubation period was in a World War II veteran
who had served as a prisoner of war in Southeast Asia and
presented with the cutaneous form of melioidosis 62 years
after initial exposure [17].
Approach: Physicians should be on high alert to a diagnosis
of melioidosis both in endemic and nonendemic regions. In
nonendemic regions, it is important to elicit even a remote his-
tory of travel to an endemic area including recreational travel,
military service and other work-related travel. It is to be noted
that symptoms may occur several years after initial exposure to
the bacteria.2.3. Inoculation and inhalation
B. pseudomallei have a natural environmental habitat in
endemic areas and are found in muddy soil, surface water and
plants. In Southeast Asia, the organism has been repeatedly
isolated from irrigated, cleared agricultural land such as paddy
ﬁelds and farms [18,19]. Most cases of melioidosis occur
following exposure to contaminated soil or water though
percutaneous inoculation via penetrating wounds and
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inoculation at the time of a snake bite has been reported [21].
Skin contact tends to have a longer incubation period with less
severe disease [7]. Inhalation via contaminated dust particles or
water droplets (bacteria in aerosol form) is the next most
common route of entry and is characterized by pneumonia and
more severe infection [7]. Acquisition of bacteria through
aspiration of contaminated water in near-drowning episodes
has been recorded [16]. Ingestion has been suggested as a mode
of acquiring infection [10]. Laboratory-acquired cases have been
described [22]. Person-to-person transmission is very uncommon.
Sexual transmission has been suggested but has not been
established [23]. Few reports suggest perinatal transmission
[24,25]. Transmission to infants through infected breast milk
from mothers with mastitis has been reported [26].
Contaminated detergents have been implicated in reports of
nosocomial infection [27,28].
Melioidosis is strongly associated with wet weather; about
75%–81% of cases occur during the rainy season [29]. Cases and
deaths from melioidosis have been found to increase linearly
with increase in mean monthly rainfall [30]. Periods of heavy
rainfall and extreme weather events such as ﬂoods and
tsunamis have been found to be associated with inhalation
transmission [31].
Approach: Inoculation and inhalation are the commonest
modes of transmission. In endemic areas, a history of regular
contact with soil, water or plants should be elicited; existing
wounds or of recent injury should be examined for. However,
absence of deﬁnite history of contact with soil or of the absence
of the evidence of a portal of entry via the skin does not rule out
the disease. Cases with pneumonic presentation during periods
of extreme wet weather events should alert the physician to
consider melioidosis as a diagnostic possibility.
2.4. Several risk factors predispose to melioidosis
(1) Age. The disease may occur at any age including new-
borns. The peak incidence is between 40 and 60 years of age, the
age range during which most co-morbid conditions develop [32].
(2) Gender. A preponderance of the disease among males has
been noted [33]; the gender difference may be due to a higher
potential for activities facilitating exposure. (3) Ethnicity.
Aboriginality was found to be a risk factor in Australia,
possibly to the potential for exposure to contaminated water
and soil [20]. (4) Occupation/recreational exposure in endemic
areas. The risk is highest for persons with regular contact with
soil or water in endemic area. Workers in the agricultural
sector, construction workers, military personnel, adventure
travelers and ecotourists are groups at high risk because of
their contact with contaminated soil or water [1]. A study in
Thailand found that 81% of cases were rice farmers [34]. (5)
Lifestyle factors. About 12%–39% of patients report a history
of heavy alcohol consumption [3]. Smoking has been identiﬁed
as a risk factor [3,35]. (6) Diet. In Australia, excessive use of
Kava (Piper methysticum root) is documented as a risk factor
[36]. (7) Co-morbid conditions. Several underlying medical
conditions or drug therapy that may impair host defense pre-
dispose to melioidosis [3,37]. Pre-existing or newly-diagnosed
type 2 diabetes mellitus is the most common co-morbid condi-
tion associated with melioidosis; about 23%–60% of melioidosis
patients were found to have associated type 2 diabetes mellitus.
In patients with cystic ﬁbrosis, B. pseudomallei may causechronic infection [38]. Other co-morbid conditions that predis-
pose to melioidosis include chronic pulmonary disease (found in
12%–27% of melioidosis cases), chronic renal disease (10%–
27%), thalassemia (7%), atypical mycobacterial disease (Myco-
bacterium tuberculosis orMycobacterium lepra), steroid therapy
(<5%) and cancer (<5%). Human immunodeﬁciency virus
infection has not been identiﬁed as a risk factor for the disease,
and it does not seem to alter the clinical features or the pro-
gression of the disease [39]; reasons for the lack of an interaction
between human immunodeﬁciency virus and melioidosis is
unclear.
Approach: About 80% of patients have one or more risk
factors; thus, knowledge of risk factors is essential. Type 2
diabetes mellitus has been found to be the commonest risk
factor; thus, a high index of suspicion among type 2 diabetic
patients is warranted. It is to be noted that otherwise healthy
persons including children may get melioidosis.
2.5. Clinical symptoms mimic other diseases
Melioidosis presents as a febrile illness with protean mani-
festation ranging from chronic localized infection to acute
fulminant septicemia with multiple organs affected. The disease
is characterized by multiple abscess formation. Table 2 provides
the salient features of clinical presentations, commonly mis-
diagnosed conditions along with certain clues to aid in
diagnosis.
Acute pulmonary infection is the most common presentation
occurring in about 50% of cases [7]. The infection may be
primary acquired via inhalation or secondary occurring via
hematogenous spread following inoculation. Patients present
with extreme prostration and toxicity that is out of proportion
to physical or radiographic ﬁndings. Clinical ﬁndings may
vary from mild undifferentiated pneumonia to severe
pneumonia or lung abscess.
Acute bacteremia may occur in about 50% of patients; the
clinical picture may vary from a simple bacteremia with no
evident focus of infection to sepsis with one/few organ
involvement to fulminant septic shock and multi-organ
involvement; about 21%–48% of cases present with septic
shock [3–5]. In northern Australia and northeast Thailand,
melioidosis has been reported to account up to 20% of
community-acquired sepsis [1]. Patients present with a history
of fever (median, 6 d; range, 3 d to several months) and often
with no focus of infection. Sepsis of abrupt onset may
progress to dissemination of the primary focus of infection
evidenced by multiple abscesses most commonly found in
spleen, liver, lung, skeletal muscle and prostate. Involvement
of joints (septic arthritis), bone (osteomyelitis), lymph nodes
(lymphadenopathy), skin (pustules) or central nervous system
(cerebral abscess, brain stem encephalitis with ﬂaccid
paralysis) may occur. Other organs rarely involved include
heart (pyopericardium, pericarditis), mycotic aneurysms,
mediastinal infection, thyroid abscess, scrotal abscesses or
epididymo-orchitis [40].
Acute localized infection, occurring in about 10% of cases,
may present as skin ulcers, subcutaneous tissue abscesses, pa-
rotid abscess or ocular infection. Localized osteomyelitis has
been described [41]. Localized infection may rapidly progress to
more widespread infection [7].
Chronic infection may occur in about 8% of cases [42].
Clinical manifestations include chronic pneumonia, chronic
Table 2
Characteristics, misdiagnosis and clues to diagnosis according to presentation type of melioidosis.
Presentation type
(occurrence), mode
of acquisition
Presenting symptoms Clinical features and
progression
Salient radiographic
features
Misdiagnosis Clues to diagnosis
Acute lung infection
(~50% of cases);
Inhalation or
hematogenous spread
following inoculation
Cough, chest pain,
high fever, headache,
anorexia
Varying picture from mild
undifferentiated pneumonia
to severe pneumonia or lung
abscess
Focal areas of
consolidation in one
or more lobes
(typically upper
lobes); lower lobe
inﬁltrates are less
common; Multiple
small nodular
opacities or patches
of alveolar inﬁltrates
(starting in upper
lobes); lesions may
coalesce or cavitate;
rapid progression to
cysts with upper lobe
predominance;
empyema (rupture of
peripheral lung
abscess)
Other community-
acquired pneumonia;
Viral pneumonia;
Mycoplasma
pneumonia;
Legionnaire's disease
Nonproductive or
productive cough
with normal sputum
is the hallmark of this
form of melioidosis;
Acute pneumonia
with upper lobe
consolidation;
Prostration and
toxicity that is out of
proportion to
physical or
radiographic ﬁndings
– rapid progression to
respiratory failure;
Mediastinal/hilar
lymphadenopathy
rare
Acute bacteremia
(simple, ~50% of
cases; with sepsis,
~20%);
Hematogenous
spread following
inoculation or
inhalation
Simple-mild febrile
illness; Sepsis-fever
(high grade and
swinging, few days-
weeks), headache,
respiratory distress,
abdominal
discomfort, joint
pain, muscle
tenderness, and
disorientation
Simple bacteremia with no
evident focus of infection;
Sepsis that usually
progresses to septic shock;
Varying picture from no
evident focus to one/few
organ involvement to
disseminated infection and
multiple organ involvement;
Characterized by abscess
formation throughout the
body – most commonly in
spleen, liver, lung, prostate
and skeletal muscles; less
common in pancreas,
kidney, CNS (cerebral
abscess, brain stem
encephalitis with ﬂaccid
paralysis), bones
(osteomyelitis), joints (septic
arthritis), skin (pustules),
lymph nodes; rarely reported
– heart (pyopericardium,
pericarditis), mycotic
aneurysms, mediastinal
infection, thyroid or scrotal
abscesses or epididymo-
orchitis.
Visceral organ
abscesses may vary
from a multitude of
microabscesses to
large abscesses with
characteristic
‘honeycomb’ or
‘Swiss cheese’
appearance most
commonly seen in
the liver; abscesses
are rarely extra-
visceral.
Other pyogenic
sepsis; Tuberculosis;
Staphylococcus
aureus infection;
Amoebic abscesses
Common in patients
with diabetes or other
comorbid conditions;
Affected organs are
not so tender as in
other pyogenic
infections; Spleen
involved more
frequently than
kidney or liver;
Imaging-
‘honeycomb’ or
‘Swiss cheese’
appearance of large
abscesses in the liver
or spleen and
simultaneous
involvement of
several organs;
Melioidosis
pericarditis-no
caseous
granulomatous
inﬂammation as in
tuberculosis
Acute localized
infection (~10% of
cases); Inoculation
Localized pain or
swelling, fever,
ulceration, abscess
Skin ulcer, nodule or
abscesses of subcutaneous
tissue (superﬁcial or deep) or
ocular infection (corneal
ulcer, hypopyon, orbital
cellulitis); lymph nodes; or
salivary glands (suppurative
parotitis, common in
children); Remains as
localized infection or may
rapidly progress to
bacteremia
Other pyogenic
abscesses; Insect
bites; Tuberculosis;
Other
ulceroglandular
lesions; Anthrax;
Leishmaniasis;
Plague; Leprosy;
Glanders; Herpes
simplex; Chancroid
Evidence of
exposure: In endemic
area, h/o contact with
soil or water;
presence of wounds
or recent injury that
would facilitate
inoculation
Chronic (~10% of
cases)
Symptoms for more
than 2 months: Fever
(high grade and
swinging), weight
loss, night sweats,
stomach or chest
pain, muscle or joint
pain, headache or
seizures
Chronic pneumonia; Chronic
skin ulcers/abscesses and
intramuscular abscesses
most common; Disseminated
infection that may progress
to sepsis
Classic upper lobe
nodules or patchy
inﬁltrates with or
without cavities
Tuberculosis;
Actinomycosis;
Fungal pneumonia;
Pyrexia of unknown
origin; Typhoid
fever; Non-infective
conditions (lung
cancer)
Characteristic
radiology appearance
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progress to sepsis.
Melioidosis is less common in children than in adults even in
endemic areas. In Thailand, about one-third of pediatric cases
presented as acute suppurative parotitis [32]. In a 24-year pro-
spective study in Northern Australia, 5% of cases were children
[43]. In this study, most children presented in the wet season and
had no known risk factor. In 42% of children, inoculation
appeared to be the mode of transmission. Primary cutaneous
manifestation was the commonest presentation (60% vs. 13% in
adults), bacteremia was less common (16% vs. 59%), and brain
stem encephalitis occurred in 3 out of 45 children. Bacteremic
children presented with pneumonia or septic arthritis/
osteomyelitis, some of whom progressed to septic shock.
Mortality was about 7%. Among the subgroup of neonates,
mortality was 72.5%. Acquisition of infection was attributed to
infected breast milk, vertical transmission associated micro
abscesses or through contaminated detergent solutions.
Regional variations in disease presentation may occur
[7,20,32,44]. Parotid abscess seen in 30%–40% of Thai children
has been reported only in one case in Australia. On the other
hand, prostatic abscess found in about 20% of Australian
males has been rarely reported elsewhere. Similarly, brain
stem encephalitis with ﬂaccid paralysis noted in 4% of cases
in northern Australia is reported in only 0.2% of Thai
population. Despite advances in treatment, the case fatality is
high. A 20-year prospective study in Australia reports a 50%
case fatality rate among adult cases with septic shock and only
4% in the absence of septic shock [3].
Approach: There is no pathognomonic feature speciﬁc to
melioidosis. Salient clinical features include patients presenting
with fever, cough, lymphadenopathy, visceral/skeletal/subcu-
taneous abscesses and/or sepsis. Rapid progression to respiratory
failure and profound weight loss are striking features. Diabetes
is the most commonly associated co-morbid condition. Some
clues may be helpful as noted in Table 2. In endemic areas, as a
rule, physicians need to expand the diagnostic work-up to
include melioidosis when confronted with clinical scenarios of:
(1) any pyrexia of unknown origin; (2) progressive pneumonia;
and (3) sepsis. Chest radiography and abdominal ultrasound are
mandatory investigations. Where available, computed tomogra-
phy scan of abdominopelvic area is useful to detect asymp-
tomatic abscesses. On imaging, ‘honeycomb or Swiss cheese’
appearance of large abscesses (commonly in liver) or small
dispersed abscesses and concurrent involvement of several or-
gans may he highly supportive of a diagnosis of melioidosis.
Pediatric melioidosis is uncommon. Diagnosis may be chal-
lenging as presenting clinical features may differ in children
compared to adults; in Northern Australia, cutaneous manifes-
tation was the commonest presentation, and in Thailand sup-
purative parotitis was most common. Neonates represent a high
risk group. A high index of clinical suspicion is necessary to
ensure prompt diagnosis and treatment.
2.6. Laboratory conﬁrmation of the disease may be
challenging
Figure 1 provides a schematic approach to the laboratory
diagnosis of melioidosis. Despite its low sensitivity, the isolation
of B. pseudomallei from blood, sputum, abscess aspirates, ce-
rebrospinal ﬂuid, pericardial ﬂuid, skin lesions or other clinical
specimens is considered as the ‘gold standard’ for a diagnosis ofmelioidosis. B. pseudomallei from sterile clinical specimens
grow easily in common bacteriological culture media such as
blood agar or MacConkey agar; however, it is often difﬁcult to
identify the organism in most laboratories even in endemic
areas. Clinical specimens from non-sterile sites will require se-
lective media such as Ashdown's selective agar or the
B. pseudomallei selective agar [45,46]. It should be noted that
when B. pseudomallei is grown from blood culture it may take
about 2–3 d for growth following subculture.
Laboratory identiﬁcation of B. pseudomallei from cultures
can be difﬁcult, especially in nonendemic countries where it is
rarely seen. B. pseudomallei colonies are large and wrinkled,
with a metallic appearance, and possesses an earthy, putrid odor
(poses major biosafety concern). Colony morphology is also
very variable and a single strain may display multiple colony
types [28]. Colonies appear like environmental contaminants and
are often discarded as being of no clinical signiﬁcance [47].
Preliminary identiﬁcation of B. pseudomallei from cultures
include: Gram staining – organism appears as a Gram-negative
rod with a characteristic ‘safety pin’ appearance (bipolar stain-
ing) and biochemical tests and the pattern of susceptibility to
antimicrobials (organism is oxidase positive, Gentamicin resis-
tant and Polymyxin resistant). The next step involves deﬁnitive
phenotypic or genotypic identiﬁcation of B. pseudomallei.
Phenotypically, B. pseudomallei can be identiﬁed using com-
mercial bacterial identiﬁcation systems such as bioMe´rieux's
Analytical Proﬁle Index 20NE and VITEK 1&VITEK 2; these
tests may fail to distinguish B. pseudomallei from the closely
related avirulent Burkholderia thailandensis in about 20% of
cases (Lau et al., 2015). More precisely, B. pseudomallei can be
identiﬁed by genotypic methods based on sequencing of 16s
rRNA and groER genes [46].
Identiﬁcation of B. pseudomallei at the molecular level by
polymerase chain reaction (PCR) assays using speciﬁc
B. pseudomallei primers continues to be a challenge due to the
existing genetic similarity between closely related species of the
Burkholderia genus [46]. Although some speciﬁc PCR assays are
available for identiﬁcation of B. pseudomallei from cultures,
they lack validation in diagnostic settings. Matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry is
one of the state of the art pathogen identiﬁcation tool used for
the rapid and accurate identiﬁcation of the B. pseudomallei from
cultures in reference laboratories [46].
Culture-based diagnosis of melioidosis may cause signiﬁcant
biosafety concerns of laboratory exposures. Hence, direct
detection of B. pseudomallei from clinical samples from sputum
or blood, using speciﬁc primers is a preferred option for rapid
diagnosis. However, there is no PCR assay with acceptable
sensitivity and speciﬁcity that is currently available. Detection of
B. pseudomallei antigen in clinical specimens using point of care
test such as lateral ﬂow assay is an upcoming approach for the
rapid diagnosis of melioidosis [48].
Antibody response and the importance of IgM/IgG detection
in melioidosis remain unclear. Hence, serological assays for the
detection of antibody response against B. pseudomallei such as
indirect haemagglutination assay, enzyme linked immunosor-
bent assay-IgM and IgG or immunochromatographic tests are at
best, only adjunct to culture-based diagnosis. Though a four-fold
rise in titer in paired serum sample (acute and convalescent)
could be conﬁrmatory of a diagnosis of melioidosis, it is only
useful in retrospective diagnosis. A result based on a single
sample is not useful in a diagnosis of melioidosis [46].
Figure 1. Schematic approach to laboratory diagnosis of melioidosis.
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ratories remains a major challenge because: culture-based
methods pose signiﬁcant biosafety risk; molecular diagnostic
assays require sophisticated laboratories; and serological assays
have poor sensitivity and speciﬁcity. Thus, a high degree of
clinical suspicion should be the key for a diagnosis of melioi-
dosis in endemic areas.
Approach: Routine baseline investigations do not help in the
diagnosis of melioidosis. Culture results may take 2–3 d and
conﬁrmatory bacterial identiﬁcation from cultures may require a
well-equipped laboratory and trained personnel. In situations
where the clinical picture is suggestive of melioidosis, and
where Gram negative bacillus is grown in culture with charac-
teristic colony morphology of B. pseudomallei without positive
conﬁrmatory tests should be considered supportive of a diag-
nosis of melioidosis.
2.7. Evidence-based criteria
In rural settings where the case volume is expected to be
high, melioidosis may be suspected but laboratories may beunequipped to identify B. pseudomallei or there may be clinical
situations when melioidosis is suspected but culture is negative.
In the above scenarios, using clinical criteria will be critical
in making a diagnosis of melioidosis. Table 3 provides
evidence-based criteria for a diagnosis of melioidosis [37,49]. As
noted in the criteria, the characteristic features of abscesses
should alert the physician to a diagnosis of melioidosis.
Other factors that should be considered along with the clinical
criteria include the evidence of exposure (residence or past travel to
endemic area, known outbreak or laboratory accident) and the
presence of major risk factors for melioidosis (type 2 diabetes
mellitus, chronic renal disease, heavy alcohol use, chronic pul-
monary disease, thalassemia, steroid therapy and malignancy).
These factors may strengthen or weaken a diagnosis of melioidosis
in a clinically suspected case. For example, in a suspected case, a
history of residence or travel to an endemic area or type 2 diabetes
mellitus would strongly support a diagnosis of melioidosis.
Approach: Evidence-based criteria along with other factors
(exposure and major risk factors) will aid in making a diagnosis
of melioidosis when laboratory conﬁrmation is either unavai-
lable or negative. It is crucial to begin empirical therapy with
Table 3
Evidence-based criteria for diagnosis of melioidosis.
Diagnosis Criteria
Deﬁnite melioidosis One or more clinical specimen
culture positive for B. pseudomallei
Probable melioidosis On ultrasound, one or more abscesses
consistent with a diagnosis of
melioidosisa but culture not
performed or negative for
B. pseudomallei or patient culture
negative on ﬁrst presentation but re-
presents to the hospital within 1
month with culture-proven
melioidosis
Possible melioidosis Clinically suspected melioidosis that
improves after an effective
antimicrobial regimen for melioidosis
or Clinically suspected melioidosis
but patient dies before improvement
could be observed
Not melioidosis Deﬁnite alternate diagnosis for
clinical manifestations leading to
suspected melioidosis or Resolution
of clinical features of suspected
melioidosis without treatment with
antimicrobial drugs that are effective
for melioidosis
a Large splenic or hepatic abscess with characteristic ‘Swiss cheese or
honeycomb’ appearance or small dispersed abscesses or parotid abscess
or prostate abscess in an endemic area where B. pseudomallei is the most
probable cause.
Source: Limmathurotsakul et al., 2010 [37]; Cheng et al., 2013 [49].
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there are very deﬁnite alternate diagnoses or resolution of sus-
pected symptoms with treatment with antimicrobial drugs that
are not used in melioidosis.Table 4
Antimicrobial regimens of melioidosis for adults and children.
Phase duration Speciﬁc indications Regimen
Intensive phase First-line agents
10–14 d
4–8 weeks for: Critically
ill; Ext pulmn. Disease;
Deep seated infection;
Organ abscesses
IV ceftazidime 50
meropenem 25 mg
25 mg/kg up to 1
For less severe cases Second-line agenta
every 4 h
Septic shock IV meropenem 25
4–8 weeks Deep focal infections:
Neurologic; Cutaneous;
Bone; Joint; Prostate
IV Ceftazidime or
with Oral SMX-TM
every 12 h
Eradication Phased
3–6 months
Oral SMX-TMP 4
alone or with oral
every 12 h
Pregnant women
children <12 y;
Intolerance or resistance
to SMX-TMP
eOral amoxicillin–
Note: All doses should be adjusted in patients with renal impairment.
a High rates of treatment failure, not recommended if ﬁrst-line agents are
phamethoxazole/Trimethoprim. In children, 30/6 mg/kg up to 1 200/240 m
perﬁcial infections (e.g., localized cutaneous), provided there are no underly
higher relapse rate. For adult patients <60 kg, a dose of 1 000/250 mg every
every 8 h is suggested. In countries where amoxicillin–clavulanate is only av
every 8 h plus amoxicillin 500 mg every 8 h to reach the required dosage i
Source: McLeod et al., 2015 [43]; Simpson et al., 1999 [50].2.8. High case fatality for failure to start appropriate
antimicrobial therapy
Melioidosis may be successfully treated with appropriate anti-
microbial therapy. Several randomized clinical trials have been
conducted to evaluate effective regimens for melioidosis. Table 4
provides treatment regimens that have been found to be useful in
adults [43,50,51]; treatment guidelines for children are currently
based on adult studies. Treatment is accomplished in two phases:
(1) Intensive phase with intravenous antimicrobial therapy for a
minimum of 10–14 d with one of the ﬁrst-line agents-ceftazi-
dime, imipenem or meropenem; sulfamethoxazole-trimethoprim is
added in cases of neurologic, cutaneous, bone, joint and prostate
involvement and the treatment period extended to 4–8 weeks.
Following initiation of therapy, patients’ blood cultures may
become negative within a few days, but it may take 10 d or longer
for patient to become afebrile [50,52]. Therapy is given until the
patient is afebrile for more than 48 h. (2) Eradication phase on
oral antimicrobial therapy for 3–6 months with sulfamethoxazole-
trimethoprim alone (commonly used in Australia) or in combina-
tion with doxycycline (commonly used in Thailand) [32].
Variations in treatment regimens may be adopted depending
on drug availability, experience in the local setting or patient
factors. For example, amoxicillin–clavulanate may be used in
intensive or the eradication phases for limited indications
(Table 4), but its use is associated with high treatment failure/
relapse rate [53].
Approach: Treatment should be initiated early in the course
of the disease since melioidosis may progress to a more severe
form and become fatal. In endemic areas where laboratory
diagnostic facilities are unavailable or delayed, empirical anti-
biotic regimens for rapidly progressing pneumonia and/or sepsis
need to cover for melioidosis. It is crucial that patients be givenAdjunctive therapy
mg/kg up to 2 g every 6 h or IV
/kg up to 1 g every 8 h or IV imipenem
g every 6 h
IV amoxicillin–clavulanate 20/5 mg/kg
mg/kg up to 1 g every 8 h IV G-CSFb 300 mg for
10 d
Meropenem or Imipenem at dose as above
Pc 40/8 mg/kg up to 1 600/320 mg
Oral Folic acid 0.1 mg/
kg up to 5 mg daily for
patients on SMX-TMP
0/8 mg/kg up to 1 600/320 mg every 12 h
doxycycline 2.5 mg/kg up to 100 mg
Oral folic acid 0.1 mg/kg
up to 5 mg daily for
patients on SMX-TMP
clavulanate 20/5 mg/kg every 8 h
available. b Granulocyte-colony stimulating factor. c SMX-TMP, Sul-
g every 12 h. d Regimen may also be used as primary treatment in su-
ing risk factors and/or dissemination to other sites. e Associated with a
8 h is suggested; for patients >60 kg, a maximum dose of 1 500/375 mg
ailable in ﬁxed 2:1 combinations (i.e., 500 mg/250 mg), then 500/250 mg
s recommended.
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phase, and is followed-up and monitored for adherence to
therapy in the eradication phase. Incomplete treatment during
the intensive phase or drug non-adherence during the eradication
phase may result in relapse or recurrence.2.9. Relapse and recurrence
Relapses and recurrence are not uncommon in melioidosis.
Relapse is the reappearance of symptoms and signs after initial
clinical response while still on antimicrobial therapy. A recurrent
infection is a new episode of melioidosis occurring after full
clinical recovery or convalescence. The rate of relapse or
recurrence may vary from 15% to 30% [21,41]. Most recurrences
are due to the original infecting strain, but reinfection with
another strain may occur [54]. Risk factors for relapse/
recurrence include: severity of disease (positive blood culture,
multifocal disease); incomplete or inadequate microbial
treatment or choice of agent (amoxicillin–clavulanate) during
the intensive phase of treatment; and improper eradication
therapy-choice of agents (amoxicillin–clavulanate, oral quino-
lones or doxycycline monotherapy), nonadherence or duration
(less than twelve weeks) [41]. It is to be noted that relapses and
recurrence may occur in immunocompromised patients despite
the full course of microbial therapy.
Just as in tuberculosis, the infection may be dormant in
melioidosis with prolonged latency (that is, infection is present
without any clinical manifestations) [41]. Reactivation from a
latent focus and recurrence into a fulminating form may occur
when host defense is compromised as in diabetes mellitus [55].
Several episodes of infections may occur in a person over
several years. Thus, patients need to be followed-up for at least
ﬁve years or more after initial recovery.
Approach: Any patient with a prior history of melioidosis and
presenting with a severe febrile illness or symptoms of sepsis
should be suspected of having a relapse/recurrence and empirical
antibiotic therapy covering B. pseudomallei should be begun
without delay. Diabetes and other conditions that compromise
host defense may predispose to relapse/recurrence. Patients need
to be informed of a lifelong risk of recurrence and that they
should provide their past history of melioidosis to their physi-
cian if they develop any severe febrile illness.2.10. Prevention measures
No vaccine is currently available. Prevention of the infection
in areas where the disease is endemic can be difﬁcult since
contact with contaminated soil is common. In endemic areas,
persons with open skin wounds and those with diabetes or other
comorbid conditions should avoid contact with soil and standing
water in these areas as they are at increased risk for acquiring
melioidosis. Wearing boots during agricultural work can prevent
infection through the feet and lower legs. In health care settings,
using standard contact precautions (mask, gloves, gown and
hand washing) is considered sufﬁcient protection. For labora-
tories, B. pseudomallei is classiﬁed as a ‘Category 3’ pathogen
because of the risk of infection to laboratory staff [1]. Therefore,
microbiological and biomedical laboratories must have adequate
facilities for safe work procedures and laboratory staff must
engage in safe work practices such as safeguards for
centrifugation, prohibiting the ‘sniff’ test (B. pseudomalleicolonies have a characteristic putrid odor) and the use of a
biological safety cabinet within a biosafety level-3 containment.
Approach: Educational interventions for prevention need to
be part of the health care messages in endemic areas. In hospital
and laboratories, adherence to standard control practices should
be evaluated on an ongoing basis to ensure compliance; that is,
infection control practices for hospitals and biosafety procedures
for laboratories.
3. Conclusions
Cases of melioidosis are often missed and the diagnosis is
delayed resulting in high case fatality in endemic areas. Because
of the severity of symptoms, patients may not delay seeking
care. Delays are most likely to be due to physicians not making a
correct diagnosis and conducting appropriate investigations or in
rural settings where laboratory facilities may be unavailable.
Early diagnosis and appropriate management is crucial in
reducing serious complications leading to high mortality, and in
preventing recurrences of the disease. Radiological imaging is
an integral part of the diagnostic workup. In situations of clin-
ically highly probable or possible cases where laboratory
bacteriological conﬁrmation is not possible, using evidence-
based criteria and empirical treatment with antimicrobial ther-
apy is recommended. It is of prime importance that patients
undergo the full course of antimicrobial therapy to avoid relapse
and recurrence. Finally, there is a crucial need for promoting
awareness among physicians at all levels and for improved
diagnostic microbiology services. Further, the need for making
the disease notiﬁable and/or initiating melioidosis registries in
endemic countries appears to be compelling.
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